Loading…
Merck & Co., Inc. is projected to rise to $162.06 by 2027, a +35% move from its current price of $120.24. MRK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $118.42 | $120.30 | $122.20 | +0.05% |
| May 30 | $117.71 | $120.35 | $123.05 | +0.09% |
| May 31 | $117.18 | $120.41 | $123.73 | +0.14% |
| Jun 1 | $116.74 | $120.46 | $124.31 | +0.19% |
| Jun 2 | $116.36 | $120.52 | $124.83 | +0.23% |
| Jun 3 | $116.02 | $120.57 | $125.30 | +0.28% |
| Jun 4 | $115.72 | $120.63 | $125.75 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $115.72 | $120.63 | $125.75 | +0.32% |
| Week 2 | $114.11 | $121.02 | $128.35 | +0.65% |
| Week 3 | $112.98 | $121.41 | $130.48 | +0.98% |
| Week 4 | $112.09 | $121.81 | $132.36 | +1.30% |
| Week 5 | $111.36 | $122.20 | $134.10 | +1.63% |
| Week 6 | $110.73 | $122.60 | $135.74 | +1.96% |
| Week 7 | $110.19 | $123.00 | $137.29 | +2.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc.
has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co., Inc. (MRK) is a healthcare company currently trading at $122.41 per share and has a market capitalization of $302.33B, ranking 42. The near-term path shows a neutral stance in 2026 with an average price equal to the current level, while the longer-term outlook points to meaningful upside through the late 2020s and into the 2030s and beyond.
Forecasts place 2026 at an average of $122.41 with a range from $106.45 to $167.15, yielding 0% ROI. The model projects bullish momentum thereafter, with rising averages and ROI through 2030 and beyond, including an average price of $235.16 in 2030 and a 92.1% ROI, continuing to climb to higher targets by 2040 and 2050.
A major floor 13.5% below — a decisive break under it would weaken the trend.
The nearest floor, 9.2% below — buyers have tended to step in here.
Price is pressing into resistance (1.8% away) — a breakout level to watch.
A major ceiling 8.5% above — clearing it would confirm fresh momentum.
Key MRK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $118.25 | Buy | $118.59 | Buy |
| MA 10 | $115.63 | Buy | $116.67 | Buy |
| MA 20 | $113.79 | Buy | $115.35 | Buy |
| MA 50 | $115.88 | Buy | $115.11 | Buy |
| MA 100 | $115.49 | Buy | $112.55 | Buy |
| MA 200 | $102.70 | Buy | $106.63 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.28 | Neutral |
| Stoch RSI (14) | 75.90 | Neutral |
| CCI (20) | 182.63 | Buy |
| Williams %R (14) | -19.50 | Info |
| MACD (12,26,9) | 1.17 | Buy |
| ROC (12) | 7.95 | Buy |
| Bollinger %B (20,2) | 0.99 | Neutral |
| Stochastic %K (14) | 80.50 | Sell |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | 3.49 | Buy |
| Ultimate (7,14,28) | 69.97 | Neutral |
| Momentum (10) | 7.87 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 121.91 | Sell |
| ADX (14) | 15.13 | Neutral |
| ATR (14) | 1.72 | Info |
The 30-day technical picture shows a range from $110.15 to $136.03 over the period. RSI14 is 70, indicating strong momentum, and the price is trading above the SMA50 of $115.70 and the SMA200 of $102.31. Support sits at $109.18, with resistance at $122.41. The overall sentiment is BULLISH.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $106.45 | $120.24 | $162.45 | 0% | Neutral | |
| $132.39 | $162.06 | $207.65 | +35% | Bullish | |
| $147.14 | $183.40 | $241.12 | +53% | Bullish | |
| $166.47 | $210.63 | $282.70 | +75% | Bullish | |
| $175.08 | $224.48 | $306.61 | +87% | Bullish | |
| $176.67 | $229.26 | $318.03 | +91% | Bullish | |
| $196.46 | $257.79 | $362.62 | +114% | Bullish | |
| $220.59 | $292.48 | $416.70 | +143% | Bullish | |
| $251.98 | $337.41 | $486.39 | +181% | Bullish | |
| $273.79 | $370.05 | $539.34 | +208% | Bullish | |
| $377.33 | $531.84 | $812.07 | +342% | Bullish | |
| $654.72 | $989.56 | $1,619.18 | +723% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $106.45 | $120.24 | $141.30 | +0.00% |
| June 2026 | $107.01 | $124.83 | $148.45 | +3.82% |
| July 2026 | $106.90 | $125.42 | $150.56 | +0.47% |
| August 2026 | $107.45 | $126.64 | $153.13 | +0.97% |
| September 2026 | $110.85 | $131.12 | $159.49 | +3.54% |
| October 2026 | $112.04 | $132.99 | $162.64 | +1.42% |
| November 2026 | $110.02 | $130.99 | $160.94 | -1.51% |
| December 2026 | $110.25 | $131.63 | $162.45 | +0.49% |
Click any year to see its month-by-month MRK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MRK is projected to trade between $106.45 and $162.45, averaging $120.24 — a potential gain of 0% from today's $120.24. A consolidation phase looks the most probable path here.
Merck & Co., Inc.'s 2027 outlook centres on $162.06, within a $132.39 to $207.65 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2028, MRK could reach as high as $241.12, with a base case around $183.40 and support toward $147.14 — roughly +53% from $120.24. Buyers look set to stay in control over this stretch.
Expect MRK to range from $166.47 to $282.70 through 2029. The $210.63 average target implies a +75% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The MRK price prediction for 2030 points to an average of $224.48 (low $175.08, high $306.61) — a potential gain of +87% on today's $120.24. Buyers look set to stay in control over this stretch.
In 2031, MRK is projected to trade between $176.67 and $318.03, averaging $229.26 — a potential gain of +91% from today's $120.24. That is up +2% on the projected 2030 average. Momentum favours further upside here.
Merck & Co., Inc.'s 2032 outlook centres on $257.79, within a $196.46 to $362.62 range. That is up +12% on the projected 2031 average. That marks a +114% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MRK could reach as high as $416.70, with a base case around $292.48 and support toward $220.59 — roughly +143% from $120.24. Momentum favours further upside here.
Expect MRK to range from $251.98 to $486.39 through 2034. The $337.41 average target implies a +181% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MRK price prediction for 2035 points to an average of $370.05 (low $273.79, high $539.34) — a potential gain of +208% on today's $120.24. Momentum favours further upside here.
In 2040, MRK is projected to trade between $377.33 and $812.07, averaging $531.84 — a potential gain of +342% from today's $120.24. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Merck & Co., Inc.'s 2050 outlook centres on $989.56, within a $654.72 to $1,619.18 range. That is up +86% on the projected 2040 average. That marks a +723% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MRK today (≈ 8.3167 MRK) could be worth
$8,229.83
+$7,229.83 (+723%) by 2050 · US Dollar
Based on the average projected MRK price of $989.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRKwould be worth at today's price.
$1,000 invested in MRK on May 27, 2025 (≈ 12.888259 MRK) would be worth
$1,549.68
+$549.68 (+55.0%) today · 1.55× · US Dollar
Based on a MRK entry price of $77.59 vs. today's $120.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $113 | $1,064.07 | +6.4% |
| 1 month ago | $110.23 | $1,090.81 | +9.1% |
| 3 months ago | $119.3 | $1,007.88 | +0.8% |
| 6 months ago | $104.83 | $1,147 | +14.7% |
| 1 year ago | $77.59 | $1,549.68 | +55.0% |
| All time (5.0y) ago | $71.74 | $1,676.13 | +67.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRK forecast.
Our base-case forecast reaches $240.00 around 2032.
Implied market cap at $240.00: $592.76B
The multi-year forecast highlights a bullish trajectory with substantial upside by 2030 and beyond. In 2030, the average price is projected at $235.16 with a ROI of 92.1 and a bullish sentiment. By 2040, the average rises to $577.75 with a ROI of 372 and continued bullish sentiment, and by 2050 the average is $1,082.97 with a ROI of 784.7, continuing the bullish trend.
The sequence also shows strong upside across 2027–2035, with the 2027 average at $167.88 (ROI 37.1) and 2028 at $190.30 (ROI 55.5), followed by steadily higher targets through 2035 at $397.61 (ROI 224.8). These figures illustrate a path of significant appreciation, acknowledging that they are estimates and not guarantees. Risks and uncertainties are inherent in any forecast.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $235.16 with a max of $321.27 and a min of $183.38, with a ROI of 92.1 and a bullish sentiment.
The forecast depicts a bullish path from 2027 onward, with rising averages and ROIs (e.g., 2027 avg $167.88, ROI 37.1; 2030 avg $235.16, ROI 92.1; 2050 avg $1,082.97, ROI 784.7). These are estimates and not guarantees.
Yes. The 2050 forecast shows an average of $1,082.97 and a max of $1,772.18, which implies a scenario where $1,000 could be reached within the forecast range.
For 2026, the min is $106.45, the avg is $122.41, and the max is $167.15, with a 0% ROI and neutral sentiment.
The 2040 forecast shows an avg price of $577.75 with a min of $409.86 and a max of $882.27, and a ROI of 372 with bullish sentiment.
Merck & Co., Inc. Community Discussion
0Share your Merck & Co., Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.